Associated Papers
Hinge binder modification into imidazopyridine for targeting actionable mutations of RET kinase.
Maturi A et al.
Rsc Medicinal Chemistry, 2025
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K et al.
European Journal of Endocrinology, 2022
Precision oncology for RET-related tumors.
Verrienti A et al.
Frontiers in Oncology, 2022
Decade in review: a new era for RET-rearranged lung cancers.
Choudhury NJ et al.
Translational Lung Cancer Research, 2020
Roles of the RET Proto-oncogene in Cancer and Development.
Takahashi M et al.
Jma Journal, 2020
5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.
Li SY et al.
Frontiers in Endocrinology, 2020
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
Plenker D et al.
Science Translational Medicine, 2017
Select a paper to view details